154 related articles for article (PubMed ID: 37418984)
1. ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways.
Li K; Quan L; Huang F; Li Y; Shen Z
Int Immunopharmacol; 2023 Sep; 122():110580. PubMed ID: 37418984
[TBL] [Abstract][Full Text] [Related]
2. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
3. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
[TBL] [Abstract][Full Text] [Related]
4. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
[TBL] [Abstract][Full Text] [Related]
5. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
6. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
[TBL] [Abstract][Full Text] [Related]
7. CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway.
Zhang H; Cao Y; Tang J; Wang R
Biomed Res Int; 2022; 2022():9944847. PubMed ID: 35813221
[TBL] [Abstract][Full Text] [Related]
8. TM6SF1 suppresses the progression of lung adenocarcinoma and M2 macrophage polarization by inactivating the PI3K/AKT/mtor pathway.
Huang S; Zhao H; Lou X; Chen D; Shi C; Ren Z
Biochem Biophys Res Commun; 2024 Jul; 718():149983. PubMed ID: 38718735
[TBL] [Abstract][Full Text] [Related]
9. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma.
Han X; Liang L; He C; Ren Q; Su J; Cao L; Zheng J
BMC Complement Med Ther; 2023 Nov; 23(1):422. PubMed ID: 37990309
[TBL] [Abstract][Full Text] [Related]
10. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
Lee KY; Shueng PW; Chou CM; Lin BX; Lin MH; Kuo DY; Tsai IL; Wu SM; Lin CW
Cancer Sci; 2020 May; 111(5):1652-1662. PubMed ID: 32133706
[TBL] [Abstract][Full Text] [Related]
11. SLITRK6 promotes the progression of lung adenocarcinoma by regulating PI3K/AKT/mTOR signaling and Warburg effect.
Yu F; Zhao X; Li M; Meng M
Apoptosis; 2023 Aug; 28(7-8):1216-1225. PubMed ID: 37219677
[TBL] [Abstract][Full Text] [Related]
12. CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Chen Y; Tang J; Lu T; Liu F
Thorac Cancer; 2020 Jul; 11(7):1848-1860. PubMed ID: 32395869
[TBL] [Abstract][Full Text] [Related]
13. Junctional adhesion molecule-like protein as a novel target for kaempferol to ameliorate lung adenocarcinoma.
Wu Q; Wang YB; Che XW; Wang H; Wang W
J Integr Med; 2023 May; 21(3):268-276. PubMed ID: 37069006
[TBL] [Abstract][Full Text] [Related]
14. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
Wu DW; Wu TC; Chen CY; Lee H
Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
[TBL] [Abstract][Full Text] [Related]
15. UHMK1 promotes lung adenocarcinoma oncogenesis by regulating the PI3K/AKT/mTOR signaling pathway.
Li Y; Wang S; Jin K; Jin W; Si L; Zhang H; Tian H
Thorac Cancer; 2023 Apr; 14(12):1077-1088. PubMed ID: 36919755
[TBL] [Abstract][Full Text] [Related]
16. NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR-TKI Resistance in Lung Adenocarcinoma.
Zhang Y; Chen B; Wang Y; Zhao Q; Wu W; Zhang P; Miao L; Sun S
Oncol Res; 2019 Jul; 27(7):751-761. PubMed ID: 30732676
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
Zhang X; Maity TK; Ross KE; Qi Y; Cultraro CM; Bahta M; Pitts S; Keswani M; Gao S; Nguyen KDP; Cowart J; Kirkali F; Wu C; Guha U
Cancer Res; 2021 Jun; 81(11):3051-3066. PubMed ID: 33727228
[TBL] [Abstract][Full Text] [Related]
18. Abnormal low expression of SFTPC promotes the proliferation of lung adenocarcinoma by enhancing PI3K/AKT/mTOR signaling transduction.
Zuo B; Wang L; Li X; Li X; Wang J; Xiong Y; Lei J; Zhang X; Chen Y; Liu Q; Jiao J; Sui M; Fan J; Wu N; Song Z; Li G
Aging (Albany NY); 2023 Nov; 15(21):12451-12475. PubMed ID: 37955668
[TBL] [Abstract][Full Text] [Related]
19. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
20. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
